FT
ALXN

Fiduciary Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Fiduciary Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-912
Closed -$111K – 521
2017
Q2 		$111K Buy
+912
New +$106K ﹤0.01% 522
2016
Q2 		– Sell
-1,531
Closed -$213K – 437
2016
Q1 		$213K Buy
1,531
+40
+3% +$5.87K 0.01% 405
2015
Q4 		$285K Sell
1,491
-788
-35% -$138K 0.01% 335
2015
Q3 		$357K Buy
2,279
+11
+0.5% +$2.01K 0.02% 307
2015
Q2 		$410K Hold
2,268
– – 0.02% 277
2015
Q1 		$393K Sell
2,268
-100
-4% -$18.1K 0.02% 278
2014
Q4 		$438K Hold
2,368
– – 0.02% 269
2014
Q3 		$393K Buy
2,368
+18
+0.8% +$2.96K 0.02% 258
2014
Q2 		$367K Hold
2,350
– – 0.02% 265
2014
Q1 		$358K Sell
2,350
-150
-6% -$23.9K 0.02% 257
2013
Q4 		$332K Hold
2,500
– – 0.01% 251
2013
Q3 		$290K Hold
2,500
– – 0.01% 260
2013
Q2 		$231K Buy
+2,500
New +$241K 0.01% 280

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fiduciary Trust's ALXN Position: Q3 2017 in Review

Fiduciary Trust sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 912 shares — an estimated $111K sold.

Fiduciary Trust first reported a position in ALXN in Q2 2013 and held it in 13 quarters. The position peaked at $438K in Q4 2014. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Fiduciary Trust reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Fiduciary Trust sold 912 Alexion Pharmaceuticals shares in Q3 2017, an estimated $111K.
  • Fiduciary Trust first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Fiduciary Trust's Alexion Pharmaceuticals position peaked at $438K in Q4 2014.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Fiduciary Trust's 13F filing for Q3 2017, filed 2 Nov 2017.